Global and China Breakthrough Therapy (BT) Designation Market 2020 by Company, Type and Application, Forecast to 2025

Table of Contents

1 Breakthrough Therapy (BT) Designation Market Overview

• 1.1 Product Overview and Scope of Breakthrough Therapy (BT) Designation
• 1.2 Classification of Breakthrough Therapy (BT) Designation by Type
  • 1.2.1 Global Breakthrough Therapy (BT) Designation Revenue by Type: 2015 VS 2019 VS 2025
  • 1.2.2 Global Breakthrough Therapy (BT) Designation Revenue Market Share by Type in 2019
  • 1.2.3 Oncology
  • 1.2.4 Infectious Diseases
  • 1.2.5 Rare Diseases
  • 1.2.6 Autoimmune Diseases
  • 1.2.7 Pulmonary Diseases
  • 1.2.8 Neurological Disorders
  • 1.2.9 Others
• 1.3 Global Breakthrough Therapy (BT) Designation Market by Application
  • 1.3.1 Overview: Global Breakthrough Therapy (BT) Designation Revenue by Application: 2015 VS 2019 VS 2025
  • 1.3.2 Hospital
  • 1.3.3 Clinic
  • 1.3.4 Research Institute
  • 1.3.5 Laboratories
• 1.4 Global Breakthrough Therapy (BT) Designation Market by Regions
  • 1.4.1 Global Breakthrough Therapy (BT) Designation Market Size by Regions: 2015 VS 2019 VS 2025
  • 1.4.2 Global Market Size of Breakthrough Therapy (BT) Designation (2015-2025)
  • 1.4.3 North America (USA, Canada and Mexico) Breakthrough Therapy (BT) Designation Status and Prospect (2015-2025)
  • 1.4.4 Europe (Germany, France, UK, Russia and Italy) Breakthrough Therapy (BT) Designation Status and Prospect (2015-2025)
  • 1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Breakthrough Therapy (BT) Designation Status and Prospect (2015-2025)
  • 1.4.6 South America (Brazil, Argentina, Colombia) Breakthrough Therapy (BT) Designation Status and Prospect (2015-2025)
  • 1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Breakthrough Therapy (BT) Designation Status and Prospect (2015-2025)

2 Company Profiles

• 2.1 Roche
  • 2.1.1 Roche Details
  • 2.1.2 Roche Major Business and Total Revenue (Financial Highlights) Analysis
  • 2.1.3 Roche SWOT Analysis
  • 2.1.4 Roche Product and Services
  • 2.1.5 Roche Breakthrough Therapy (BT) Designation Revenue, Gross Margin and Market Share (2018-2019)
• 2.2 Sanofi
  • 2.2.1 Sanofi Details
  • 2.2.2 Sanofi Major Business and Total Revenue (Financial Highlights) Analysis
  • 2.2.3 Sanofi SWOT Analysis
  • 2.2.4 Sanofi Product and Services
  • 2.2.5 Sanofi Breakthrough Therapy (BT) Designation Revenue, Gross Margin and Market Share (2018-2019)
• 2.3 Janssen
  • 2.3.1 Janssen Details
  • 2.3.2 Janssen Major Business and Total Revenue (Financial Highlights) Analysis
  • 2.3.3 Janssen SWOT Analysis
  • 2.3.4 Janssen Product and Services
  • 2.3.5 Janssen Breakthrough Therapy (BT) Designation Revenue, Gross Margin and Market Share (2018-2019)
• 2.4 Abbvie
  • 2.4.1 Abbvie Details
  • 2.4.2 Abbvie Major Business and Total Revenue (Financial Highlights) Analysis
  • 2.4.3 Abbvie SWOT Analysis
  • 2.4.4 Abbvie Product and Services
  • 2.4.5 Abbvie Breakthrough Therapy (BT) Designation Revenue, Gross Margin and Market Share (2018-2019)
• 2.5 Gilead
  • 2.5.1 Gilead Details
  • 2.5.2 Gilead Major Business and Total Revenue (Financial Highlights) Analysis
  • 2.5.3 Gilead SWOT Analysis
  • 2.5.4 Gilead Product and Services
  • 2.5.5 Gilead Breakthrough Therapy (BT) Designation Revenue, Gross Margin and Market Share (2018-2019)
• 2.6 Novartis International AG
  • 2.6.1 Novartis International AG Details
  • 2.6.2 Novartis International AG Major Business and Total Revenue (Financial Highlights) Analysis
  • 2.6.3 Novartis International AG SWOT Analysis
  • 2.6.4 Novartis International AG Product and Services
  • 2.6.5 Novartis International AG Breakthrough Therapy (BT) Designation Revenue, Gross Margin and Market Share (2018-2019)
• 2.7 Acadia
  • 2.7.1 Acadia Details
  • 2.7.2 Acadia Major Business and Total Revenue (Financial Highlights) Analysis
  • 2.7.3 Acadia SWOT Analysis
  • 2.7.4 Acadia Product and Services
  • 2.7.5 Acadia Breakthrough Therapy (BT) Designation Revenue, Gross Margin and Market Share (2018-2019)
• 2.8 Eli Lilly
  • 2.8.1 Eli Lilly Details
  • 2.8.2 Eli Lilly Major Business and Total Revenue (Financial Highlights) Analysis
  • 2.8.3 Eli Lilly SWOT Analysis
  • 2.8.4 Eli Lilly Product and Services
  • 2.8.5 Eli Lilly Breakthrough Therapy (BT) Designation Revenue, Gross Margin and Market Share (2018-2019)
• 2.9 BMS
  • 2.9.1 BMS Details
  • 2.9.2 BMS Major Business and Total Revenue (Financial Highlights) Analysis
  • 2.9.3 BMS SWOT Analysis
  • 2.9.4 BMS Product and Services
  • 2.9.5 BMS Breakthrough Therapy (BT) Designation Revenue, Gross Margin and Market Share (2018-2019)
• 2.10 Regeneron
  • 2.10.1 Regeneron Details
  • 2.10.2 Regeneron Major Business and Total Revenue (Financial Highlights) Analysis
  • 2.10.3 Regeneron SWOT Analysis
  • 2.10.4 Regeneron Product and Services
  • 2.10.5 Regeneron Breakthrough Therapy (BT) Designation Revenue, Gross Margin and Market Share (2018-2019)
• 2.11 Vertex
  • 2.11.1 Vertex Details
  • 2.11.2 Vertex Major Business and Total Revenue (Financial Highlights) Analysis
  • 2.11.3 Vertex SWOT Analysis
  • 2.11.4 Vertex Product and Services
  • 2.11.5 Vertex Breakthrough Therapy (BT) Designation Revenue, Gross Margin and Market Share (2018-2019)
• 2.12 Jazz Pharmaceuticals
  • 2.12.1 Jazz Pharmaceuticals Details
  • 2.12.2 Jazz Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
  • 2.12.3 Jazz Pharmaceuticals SWOT Analysis
  • 2.12.4 Jazz Pharmaceuticals Product and Services
  • 2.12.5 Jazz Pharmaceuticals Breakthrough Therapy (BT) Designation Revenue, Gross Margin and Market Share (2018-2019)
• 2.13 Boehringer Ingelheim
  • 2.13.1 Boehringer Ingelheim Details
  • 2.13.2 Boehringer Ingelheim Major Business and Total Revenue (Financial Highlights) Analysis
  • 2.13.3 Boehringer Ingelheim SWOT Analysis
  • 2.13.4 Boehringer Ingelheim Product and Services
  • 2.13.5 Boehringer Ingelheim Breakthrough Therapy (BT) Designation Revenue, Gross Margin and Market Share (2018-2019)
• 2.14 Eisai
  • 2.14.1 Eisai Details
  • 2.14.2 Eisai Major Business and Total Revenue (Financial Highlights) Analysis
  • 2.14.3 Eisai SWOT Analysis
  • 2.14.4 Eisai Product and Services
  • 2.14.5 Eisai Breakthrough Therapy (BT) Designation Revenue, Gross Margin and Market Share (2018-2019)
• 2.15 Alexion
  • 2.15.1 Alexion Details
  • 2.15.2 Alexion Major Business and Total Revenue (Financial Highlights) Analysis
  • 2.15.3 Alexion SWOT Analysis
  • 2.15.4 Alexion Product and Services
  • 2.15.5 Alexion Breakthrough Therapy (BT) Designation Revenue, Gross Margin and Market Share (2018-2019)
• 2.16 GlaxoSmithKline
  • 2.16.1 GlaxoSmithKline Details
  • 2.16.2 GlaxoSmithKline Major Business and Total Revenue (Financial Highlights) Analysis
  • 2.16.3 GlaxoSmithKline SWOT Analysis
  • 2.16.4 GlaxoSmithKline Product and Services
  • 2.16.5 GlaxoSmithKline Breakthrough Therapy (BT) Designation Revenue, Gross Margin and Market Share (2018-2019)
• 2.17 Amgen
  • 2.17.1 Amgen Details
  • 2.17.2 Amgen Major Business and Total Revenue (Financial Highlights) Analysis
  • 2.17.3 Amgen SWOT Analysis
  • 2.17.4 Amgen Product and Services
  • 2.17.5 Amgen Breakthrough Therapy (BT) Designation Revenue, Gross Margin and Market Share (2018-2019)
• 2.18 Exelixis
  • 2.18.1 Exelixis Details
  • 2.18.2 Exelixis Major Business and Total Revenue (Financial Highlights) Analysis
  • 2.18.3 Exelixis SWOT Analysis
  • 2.18.4 Exelixis Product and Services
  • 2.18.3 Exelixis Breakthrough Therapy (BT) Designation Revenue, Gross Margin and Market Share (2018-2019)
• 2.19 Merck
  • 2.19.1 Merck Details
  • 2.19.2 Merck Major Business and Total Revenue (Financial Highlights) Analysis
  • 2.19.3 Merck SWOT Analysis
  • 2.19.4 Merck Product and Services
  • 2.19.5 Merck Breakthrough Therapy (BT) Designation Revenue, Gross Margin and Market Share (2018-2019)
• 2.20 AstraZeneca
  • 2.20.1 AstraZeneca Details
  • 2.20.2 AstraZeneca Major Business and Total Revenue (Financial Highlights) Analysis
  • 2.20.3 AstraZeneca SWOT Analysis
  • 2.20.4 AstraZeneca Product and Services
  • 2.20.5 AstraZeneca Breakthrough Therapy (BT) Designation Revenue, Gross Margin and Market Share (2018-2019)
• 2.21 Takeda
  • 2.21.1 Takeda Details
  • 2.21.2 Takeda Major Business and Total Revenue (Financial Highlights) Analysis
  • 2.21.3 Takeda SWOT Analysis
  • 2.21.4 Takeda Product and Services
  • 2.21.5 Takeda Breakthrough Therapy (BT) Designation Revenue, Gross Margin and Market Share (2018-2019)
• 2.22 Pfizer
  • 2.22.1 Pfizer Details
  • 2.22.2 Pfizer Major Business and Total Revenue (Financial Highlights) Analysis
  • 2.22.3 Pfizer SWOT Analysis
  • 2.22.4 Pfizer Product and Services
  • 2.22.5 Pfizer Breakthrough Therapy (BT) Designation Revenue, Gross Margin and Market Share (2018-2019)

3 Market Competition, by Players

• 3.1 Global Breakthrough Therapy (BT) Designation Revenue and Share by Players (2015-2020)
• 3.2 Market Concentration Rate
  • 3.2.1 Top 5 Breakthrough Therapy (BT) Designation Players Market Share
  • 3.2.2 Top 10 Breakthrough Therapy (BT) Designation Players Market Share
• 3.3 Market Competition Trend

4 Market Size by Regions

• 4.1 Global Breakthrough Therapy (BT) Designation Revenue and Market Share by Regions
• 4.2 North America Breakthrough Therapy (BT) Designation Revenue and Growth Rate (2015-2020)
• 4.3 Europe Breakthrough Therapy (BT) Designation Revenue and Growth Rate (2015-2020)
• 4.4 Asia-Pacific Breakthrough Therapy (BT) Designation Revenue and Growth Rate (2015-2020)
• 4.5 South America Breakthrough Therapy (BT) Designation Revenue and Growth Rate (2015-2020)
• 4.6 Middle East & Africa Breakthrough Therapy (BT) Designation Revenue and Growth Rate (2015-2020)

5 North America Breakthrough Therapy (BT) Designation Revenue by Countries

• 5.1 North America Breakthrough Therapy (BT) Designation Revenue by Countries (2015-2020)
• 5.2 USA Breakthrough Therapy (BT) Designation Revenue and Growth Rate (2015-2020)
• 5.3 Canada Breakthrough Therapy (BT) Designation Revenue and Growth Rate (2015-2020)
• 5.4 Mexico Breakthrough Therapy (BT) Designation Revenue and Growth Rate (2015-2020)

6 Europe Breakthrough Therapy (BT) Designation Revenue by Countries

• 6.1 Europe Breakthrough Therapy (BT) Designation Revenue by Countries (2015-2020)
• 6.2 Germany Breakthrough Therapy (BT) Designation Revenue and Growth Rate (2015-2020)
• 6.3 UK Breakthrough Therapy (BT) Designation Revenue and Growth Rate (2015-2020)
• 6.4 France Breakthrough Therapy (BT) Designation Revenue and Growth Rate (2015-2020)
• 6.5 Russia Breakthrough Therapy (BT) Designation Revenue and Growth Rate (2015-2020)
• 6.6 Italy Breakthrough Therapy (BT) Designation Revenue and Growth Rate (2015-2020)

7 Asia-Pacific Breakthrough Therapy (BT) Designation Revenue by Countries

• 7.1 Asia-Pacific Breakthrough Therapy (BT) Designation Revenue by Countries (2015-2020)
• 7.2 China Breakthrough Therapy (BT) Designation Revenue and Growth Rate (2015-2020)
• 7.3 Japan Breakthrough Therapy (BT) Designation Revenue and Growth Rate (2015-2020)
• 7.4 Korea Breakthrough Therapy (BT) Designation Revenue and Growth Rate (2015-2020)
• 7.5 India Breakthrough Therapy (BT) Designation Revenue and Growth Rate (2015-2020)
• 7.6 Southeast Asia Breakthrough Therapy (BT) Designation Revenue and Growth Rate (2015-2020)

8 South America Breakthrough Therapy (BT) Designation Revenue by Countries

• 8.1 South America Breakthrough Therapy (BT) Designation Revenue by Countries (2015-2020)
• 8.2 Brazil Breakthrough Therapy (BT) Designation Revenue and Growth Rate (2015-2020)
• 8.3 Argentina Breakthrough Therapy (BT) Designation Revenue and Growth Rate (2015-2020)

9 Middle East & Africa Revenue Breakthrough Therapy (BT) Designation by Countries

• 9.1 Middle East & Africa Breakthrough Therapy (BT) Designation Revenue by Countries (2015-2020)
• 9.2 Saudi Arabia Breakthrough Therapy (BT) Designation Revenue and Growth Rate (2015-2020)
• 9.3 UAE Breakthrough Therapy (BT) Designation Revenue and Growth Rate (2015-2020)
• 9.4 Egypt Breakthrough Therapy (BT) Designation Revenue and Growth Rate (2015-2020)
• 9.5 South Africa Breakthrough Therapy (BT) Designation Revenue and Growth Rate (2015-2020)

10 Market Size Segment by Type

• 10.1 Global Breakthrough Therapy (BT) Designation Revenue and Market Share by Type (2015-2020)
• 10.2 Global Breakthrough Therapy (BT) Designation Market Forecast by Type (2019-2024)
• 10.3 Oncology Revenue Growth Rate (2015-2025)
• 10.4 Infectious Diseases Revenue Growth Rate (2015-2025)
• 10.5 Rare Diseases Revenue Growth Rate (2015-2025)
• 10.6 Autoimmune Diseases Revenue Growth Rate (2015-2025)
• 10.7 Pulmonary Diseases Revenue Growth Rate (2015-2025)
• 10.8 Neurological Disorders Revenue Growth Rate (2015-2025)
• 10.9 Others Revenue Growth Rate (2015-2025)

11 Global Breakthrough Therapy (BT) Designation Market Segment by Application

• 11.1 Global Breakthrough Therapy (BT) Designation Revenue Market Share by Application (2015-2020)
• 11.2 Breakthrough Therapy (BT) Designation Market Forecast by Application (2019-2024)
• 11.3 Hospital Revenue Growth (2015-2020)
• 11.4 Clinic Revenue Growth (2015-2020)
• 11.5 Research Institute Revenue Growth (2015-2020)
• 11.6 Laboratories Revenue Growth (2015-2020)

12 Global Breakthrough Therapy (BT) Designation Market Size Forecast (2021-2025)

• 12.1 Global Breakthrough Therapy (BT) Designation Market Size Forecast (2021-2025)
• 12.2 Global Breakthrough Therapy (BT) Designation Market Forecast by Regions (2021-2025)
• 12.3 North America Breakthrough Therapy (BT) Designation Revenue Market Forecast (2021-2025)
• 12.4 Europe Breakthrough Therapy (BT) Designation Revenue Market Forecast (2021-2025)
• 12.5 Asia-Pacific Breakthrough Therapy (BT) Designation Revenue Market Forecast (2021-2025)
• 12.6 South America Breakthrough Therapy (BT) Designation Revenue Market Forecast (2021-2025)
• 12.7 Middle East & Africa Breakthrough Therapy (BT) Designation Revenue Market Forecast (2021-2025)

13 Research Findings and Conclusion

14 Appendix

• 14.1 Methodology
• 14.2 Data Source
• 14.3 Disclaimer